

Special Issue

Advances in SARS-CoV-2 Infection

Message from the Guest Editor

More than a year has passed since the new coronavirus SARS-CoV-2 entered our lives, causing worldwide grief and economic devastation in the form of COVID-19. COVID-19 is multifaceted, with a variety of clinical expressions from mild or moderate symptoms that generally heal without the need for any treatment, to more severe and devastating effects.

In the therapeutic field, there is still no definitive curative drug. However, several currently available vaccines were manufactured in just 18 months. The positive effects of the vaccination campaign are being seen in many parts of the world. However, the disappearance of this new infection is still far from being a reality, as it is also threatened by the presence of numerous viral variants.

The purpose of this Special Issue is to focus on the main biological, epidemiological and clinical aspects of the virus, but above all on therapeutic and preventive aspects in the light of the newly acquired knowledge.

Guest Editor

Prof. Dr. Carlo Contini

Infectious and Tropical Diseases, University of Ferrara, Ferrara, Italy

Deadline for manuscript submissions

closed (20 December 2022)



Microorganisms

an Open Access Journal
by MDPI

Impact Factor 4.2
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/108688

Microorganisms
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
microorganisms@mdpi.com

[mdpi.com/journal/
microorganisms](https://mdpi.com/journal/microorganisms)





Microorganisms

an Open Access Journal
by MDPI

Impact Factor 4.2
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
microorganisms](https://mdpi.com/journal/microorganisms)



About the Journal

Message from the Editor-in-Chief

"Microorganism" merges the idea of the very small with the idea of the evolving reproducing organism is a unifying principle for the discipline of microbiology. Our journal recognizes the broadly diverse yet connected nature of microorganisms and provides an advanced publishing forum for original articles from scientists involved in high-quality basic and applied research on any prokaryotic or eukaryotic microorganism, and for research on the ecology, genomics and evolution of microbial communities as well as that exploring cultured microorganisms in the laboratory.

Editor-in-Chief

Dr. Nico Jehmlich

Department of Molecular Toxicology, UFZ-Helmholtz Centre for
Environmental Research, 04318 Leipzig, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, PubAg, CAPlus / SciFinder, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Microbiology) / CiteScore - Q1 (Microbiology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.2 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).